Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Innovation And Integrity Will Be Goodman's Role Under Reorganization

Executive Summary

FDA's Office of Chief Scientist will lose some specific responsibilities but gain a broader mission under a reorganization proposed by Commissioner Margaret Hamburg

You may also be interested in...

FDA Regulatory Science Infrastructure Gets $25 Million Push In Budget

Gaining the expertise and infrastructure needed to assess products of the future - such as biosimilars and those based on stem cells and nanotechnology - is the goal of a $25 million scientific modernization effort proposed in the fiscal 2011 FDA budget

FDA Continues "Tayloring" Senior Leadership

BIO executive VP John Taylor returns to the agency as special counselor while FDA also fills another key liaison slot.

FDA Reorganization Elevates Scientific And Food Safety Priorities

The FDA Commissioner says the realignment of four deputy-level offices in the Office of the Commissioner will streamline "common activities" and strengthen science and food safety

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts